EP4384222A4 - GO-2-ME and RGO-2-ME hybrids, methods for their production and their use - Google Patents

GO-2-ME and RGO-2-ME hybrids, methods for their production and their use

Info

Publication number
EP4384222A4
EP4384222A4 EP22856321.9A EP22856321A EP4384222A4 EP 4384222 A4 EP4384222 A4 EP 4384222A4 EP 22856321 A EP22856321 A EP 22856321A EP 4384222 A4 EP4384222 A4 EP 4384222A4
Authority
EP
European Patent Office
Prior art keywords
rgo
hybrids
production
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22856321.9A
Other languages
German (de)
French (fr)
Other versions
EP4384222A1 (en
Inventor
Magdalena Gorska-Ponikowska
Ludwika Lipinska
Joanna Gieraltowska
Magdalena Baran
Adrian Chlanda
Krystian Kowiorski
Lucyna Konieczna
Mariusz Belka
Anna Kamm
Alicja Kuban-Jankowska
Jacek Gulczynski
Ewa Izycka-Swieszewska
Narcyz Knap
Aleksander Zolnierski
Tomasz Baczek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical University of Gdańsk
Lukasiewicz Research Network - Institute of Microelectronics and Photonics
Original Assignee
Medical University of Gdańsk
Lukasiewicz Research Network - Institute of Microelectronics and Photonics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical University of Gdańsk, Lukasiewicz Research Network - Institute of Microelectronics and Photonics filed Critical Medical University of Gdańsk
Publication of EP4384222A1 publication Critical patent/EP4384222A1/en
Publication of EP4384222A4 publication Critical patent/EP4384222A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Ceramic Engineering (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22856321.9A 2021-08-13 2022-08-12 GO-2-ME and RGO-2-ME hybrids, methods for their production and their use Pending EP4384222A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL438737A PL243445B1 (en) 2021-08-13 2021-08-13 GO-2-ME and rGO 2-ME hybrids, method of their preparation and application
PCT/PL2022/050050 WO2023018342A1 (en) 2021-08-13 2022-08-12 Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application

Publications (2)

Publication Number Publication Date
EP4384222A1 EP4384222A1 (en) 2024-06-19
EP4384222A4 true EP4384222A4 (en) 2026-05-20

Family

ID=85200946

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22856321.9A Pending EP4384222A4 (en) 2021-08-13 2022-08-12 GO-2-ME and RGO-2-ME hybrids, methods for their production and their use

Country Status (3)

Country Link
EP (1) EP4384222A4 (en)
PL (1) PL243445B1 (en)
WO (1) WO2023018342A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL449413A1 (en) * 2024-07-30 2026-02-02 Gdański Uniwersytet Medyczny Pharmaceutical composition, preparation containing the pharmaceutical composition and their use in the treatment of skin cancers
PL450037A1 (en) * 2024-10-15 2026-04-20 Wojskowa Akademia Techniczna Im. Jarosława Dąbrowskiego Graphene oxide suspension for aerosol administration and its application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2532449A (en) * 2014-11-19 2016-05-25 Univ Manchester Use of Nanomaterials in treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN CHENGQUN ET AL: "Single-Walled Carbon Nanotubes Mediated Neovascularity Targeted Antitumor Drug Delivery System", JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 16, no. 1, 16 January 2013 (2013-01-16), CA, pages 40, XP093384985, ISSN: 1482-1826, DOI: 10.18433/j3h02c *
See also references of WO2023018342A1 *
SINGH MANJRI ET AL: "In vitro cytotoxicity of GO–DOx on FaDu squamous carcinoma cell lines", INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. Volume 13, 1 March 2018 (2018-03-01), New Zealand, pages 107 - 111, XP093385268, ISSN: 1178-2013, DOI: 10.2147/ijn.s124891 *
ZHANG ZHENZHONG ET AL: "Photodynamic therapy of a 2-methoxyestradiol tumor-targeting drug delivery system mediated by Asn-Gly-Arg in breast cancer", INTERNATIONAL JOURNAL OF NANOMEDICINE, 1 April 2013 (2013-04-01), New Zealand, pages 1551, XP093384986, ISSN: 1178-2013, DOI: 10.2147/ijn.s40011 *

Also Published As

Publication number Publication date
PL438737A1 (en) 2023-02-20
EP4384222A1 (en) 2024-06-19
WO2023018342A1 (en) 2023-02-16
PL243445B1 (en) 2023-08-28

Similar Documents

Publication Publication Date Title
EP3854877A4 (en) MODIFIED T LYMPHOCYTE, METHOD FOR PREPARATION AND USE
EP4245873C0 (en) CREEP-RESISTANT, DURABLE, NICKEL-BASED FORMING SUPERALLOY AND METHODS FOR ITS PRODUCTION AND USE
EP4019121A4 (en) SUPER WET SURFACE AND METHOD FOR PRODUCING THEREOF AND USE THEREOF
EP4018501A4 (en) ION-CONDUCTING STRUCTURES, DEVICES WITH ION-CONDUCTING STRUCTURES AND METHODS FOR THEIR USE AND PRODUCTION
EP4039803A4 (en) GMO HUMAN IMMUNE CELLS, PROCESS FOR THEIR PRODUCTION AND THEIR USE
EP4365967C0 (en) SOLAR CELL AND METHOD FOR ITS MANUFACTURE
EP2410926A4 (en) BALLOON EQUIPMENT AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3858818A4 (en) TRIKETON COMPOUND, PROCESS FOR ITS PRODUCTION AND USE, AND HERBICIDE
EP4097155C0 (en) Actinically crosslinkable polysiloxane-polyglycerol block copolymers, processes for their preparation and their use
EP3936495C0 (en) GAS-GENERATING AGENT COMPOSITION, METHOD FOR ITS PRODUCTION AND ITS USE
EP3954694A4 (en) UBIQUITIN-SPECIFIC PROTEAS INHIBITORS, PROCESSES FOR THEIR PRODUCTION AND THEIR USE
EP3936504A4 (en) PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
EP4037003A4 (en) ASYNCHRONE HEATING AND CALENDARING DEVICE, LARGE WIDTH ULTRA-THIN LITHIUM METAL FOIL, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
EP4047113A4 (en) POLYAMIDE ISLAND FIBER, PROCESS FOR THE PRODUCTION THEREOF AND USE THEREOF
EP4039799A4 (en) MANIPULATED IMMUNE KILLER CELL, METHOD FOR PRODUCTION THEREOF AND USE THEREOF
EP4039687A4 (en) TETRACYCLIC PYRIMIDINONE COMPOUND, METHOD FOR PREPARATION THEREOF, COMPOSITION AND USE THEREOF
EP4150240C0 (en) HOSE ARRANGEMENT AND METHOD FOR ITS MANUFACTURE AND USE
EP4401780A4 (en) AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THEIR USE
ATE509923T1 (en) DERIVATIVES OF 7-ALKYNYL-1,8-NAPHTHHYRIDONES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN THERAPEUTICS
ATE517092T1 (en) TETRAHYDRONAPHTHALINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTI-INFLAMMATORY
EP4022104A4 (en) MAGNESIUM ALLOY BASED ARTICLES AND METHODS FOR THEIR PRODUCTION AND USE THEREOF
EP3929180C0 (en) Quinoline carbonic acid ester compound and method for its preparation and use
EP4015625A4 (en) UNIVERSAL CAR-T CELL AND METHODS FOR THE PRODUCTION AND USE THEREOF
EP3929181A4 (en) 6-OXO-1,6-DIHYDROPYRIDAZINE PRODRUG DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE IN MEDICINE
EP4033912A4 (en) Titanium dioxide free white film coating composition, process for preparing the same and method of use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0047520000

Ipc: A61K0047690000

A4 Supplementary search report drawn up and despatched

Effective date: 20260421

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/69 20170101AFI20260416BHEP

Ipc: A61K 47/52 20170101ALI20260416BHEP

Ipc: A61P 35/00 20060101ALI20260416BHEP

Ipc: A61K 31/565 20060101ALI20260416BHEP

Ipc: A61K 33/44 20060101ALI20260416BHEP

Ipc: B82Y 5/00 20110101ALI20260416BHEP